Clinical Trials
9 trialsNCT04956640 2026-05-29
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT03485209 2026-04-20
innovaTV 207
Seagen Inc.
Phase 2 Active not recruiting
NCT05945823 2026-04-09
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT04953962 2023-08-15
Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
CanBas Co. Ltd.
Phase 2 Completed
NCT03102320 2022-06-30
ARCS-Multi
Bayer
Phase 1 Completed
NCT02433626 2019-02-01
COTI2-101
Critical Outcome Technologies Inc.
Phase 1 Unknown
NCT00101907 2014-03-20
Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer
Amgen
Phase 1 Terminated